CoChat

Glucagon-Like Peptide 1 Improves the Ability of the β-Cell to Sense and Respond to Glucose in Subjects With Impaired Glucose Tolerance

Byrne, Maria M, Gliem, Katja, Wank, Uwe, Arnold, Rudolf, Katschinski, Martin, Polonsky, Kenneth S, Goke, Burkhard · 1998 · Diabetes
Cited by 55

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Impaired glucose tolerance (IGT) and NIDDM are both associated with an impaired ability of the β-Cell to sense and respond to small changes in plasma glucose concentrations. The aim of this study was to establish if glucagon-like peptide 1 (GLP-1), a natural enteric peptide and potent insulin secretagogue, improves this defect. Two weight-matched groups, one with eight subjects having IGT (2-h glucose, 10.1 ± 0.3 mmol/l) and another with seven subjects with diet-treated NIDDM (2-h glucose, 14.5 ± 0.9 mmol/l), were studied on two occasions during a 12-h oscillatory glucose infusion, a sensitive test of the ability of the β-Cell to sense and respond to glucose. Glucose was infused with a mean rate of 4 mg · kg−1 · min−1, amplitude 33% above and below the mean rate, and periodicity of 144 min, with infusion of saline or GLP-1 at 0.4 pmol · kg−1 · min−1 for 12 h. Mean glucose levels were significantly lower in both groups during the GLP-1 infusion compared with during saline infusion: 9.2 ± 0.4 vs. 6.4 ±0.1 mmol/l in the IGT subjects (P < 0.0004) and 14.6 ± 1.0 vs. 9.3 ± 0.7 mmol/L in NIDDM subjects (P < 0.0002). Despite this significant reduction in plasma glucose concentration, insulin secretion rates (ISRs) increased significantly in IGT subjects (513.3 ± 77.6 vs. 583.1 ± 100.7 pmol/min; P < 0.03), with a trend toward increasing in NIDDM subjects (561.7 ± 122.16 vs. 642.8 ± 128 pmol/min; P = 0.1). These results were compatible with enhanced insulin secretion in the presence of GLP-1. Spectral power was used as a measure of the ability of the β-Cell to secrete insulin in response to small changes in the plasma glucose concentration during the oscillatory infusion. Spectral power for ISR increased from 2.1 ± 0.9 during saline infusion to 7.4 ±1.3 during GLP-1 infusion in IGT subjects (P < 0.004), but was unchanged in NIDDM subjects (1.0 ± 0.4 to 1.5 ± 0.6; P = 0.3). We concluded that low dosage GLP-1 improves the ability of the β-Cell to secrete insulin in both IGT and NIDDM subjects, but that the ability to sense and respond to subtle changes in plasma glucose is improved in IGT subjects, with only a variable response in NIDDM subjects. β-Cell dysfunction was improved by GLP-1 infusion, suggesting that early GLP-1 therapy may preserve β-Cell function in subjects with IGT or mild NIDDM

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diab.47.8.1259

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 55

Metadata

Authors
Byrne, M. M., Gliem, K., Wank, U., Arnold, R., Katschinski, M., Polonsky, K. S., & Goke, B.
Venue
Diabetes
Published
1998-08-01
Volume
47
Issue
8
Pages
1259-1265
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2013842626
Cited by
55
References
5
FWCI
2.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-Like Peptide 1 Improves the Ability of the β-Cell to Sense and Respond to Glucose in Subjects With Impaired Glucose Tolerance. https://app.cochat.ai/papers/10.2337/diab.47.8.1259
The paper
Byrne, M. M., Gliem, K., Wank, U., Arnold, R., Katschinski, M., Polonsky, K. S., & Goke, B. (1998). Glucagon-Like Peptide 1 Improves the Ability of the β-Cell to Sense and Respond to Glucose in Subjects With Impaired Glucose Tolerance. Diabetes. https://doi.org/10.2337/diab.47.8.1259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.